cf-SUPER ctDNA Analysis Technology

Circulating tumor DNA detection and analysis system for cancer diagnosis and monitoring. Enables early cancer detection through blood-based liquid biopsy technology with high sensitivity and specificity.

Comprehensive diagnostic solutions for cancer detection and treatment monitoring utilizing FISH and circulating tumor cell (CTC) detection technology. These solutions enable personalized medicine approaches and targeted therapy delivery.

Comprehensive genomic sequencing platform for cancer diagnosis and characterization. Utilizes next-generation sequencing technology to identify genetic mutations and alterations in tumor samples. Supports treatment selection and clinical decision-making for oncology patients.

A diagnostic product utilizing GeneCker's ultra-precision CRISPR/Cas9 technology for genetic analysis. Part of GeneCker's one-stop cancer diagnosis platform that includes sample collection, DNA sequencing, and data output capabilities.

Custom NGS panels for targeted resequencing using Cell3 Target technology to convert cell-free DNA (cfDNA), genomic DNA (gDNA), and formalin-fixed paraffin-embedded (FFPE) DNA into libraries for next-generation sequencing. The panels are validated for ctDNA, gDNA, and FFPE DNA samples for oncology applications including early cancer detection and cancer monitoring. They incorporate error suppression technology with unique molecular indexes (UMIs) and unique dual indexes (UDIs) to enable confident variant calling down to 0.1% VAF, with support for as little as 1 ng of genomic or cfDNA input and 10 ng of FFPE material.

Integrated platform for cancer diagnosis utilizing liquid biopsy techniques with CRISPR/Cas9 technology. Includes complete workflow from sample collection through DNA sequencing to result analysis.

A cancer diagnosis platform product utilizing GeneCker's ultra-precision CRISPR/Cas9 technology for standardization of liquid biopsy diagnosis. Integrates sample collection, DNA sequencing via NGS or Sanger sequencing methods, and provides results in result booklet or PDF format.

A diagnostic product utilizing GeneCker's ultra-precision CRISPR/Cas9 technology for genetic analysis. Part of GeneCker's one-stop cancer diagnosis platform that includes sample collection, DNA sequencing, and data output capabilities.

An independently developed platform for detecting circulating tumor DNA with high sensitivity and specificity compared to traditional detection methods. This liquid biopsy approach enables non-invasive, painless diagnosis through a single blood sample for comprehensive cancer patient support.

Molecular diagnostic test using CRISPR/Cas9 technology to identify and amplify mutant DNA sequences in patient samples. Provides standardized detection and quantification of cancer-related genetic mutations.

Liquid-based cytology combined with automated FISH technology for enhanced cancer diagnostic accuracy. This integrated approach delivers reliable cytological and genetic analysis in a single workflow.

HCCscreen is a cancer early detection technology and service based on circulating free DNA (cfDNA) and blood biomarkers for hepatocellular carcinoma screening. Clinical data from 1,615 asymptomatic individuals demonstrated 88% sensitivity and 93% specificity, outperforming ultrasound screening which showed 71% sensitivity and 95% specificity. The service is available through hospital networks, government screening programs, physical examination centers, and online health platforms.